Recent Updates
Recently added Catalysts

Paxlovid

Phase 3

COVID-19 | Small molecule | Infectious Disease |Unity Biotechnology, Inc.|Last Updated: May 16, 2025

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedNO_TREATMENT_CONTROLLEDDMC
Total Trials1
Total Enrollment797
FDA Designations
No designations recorded
Clinical trial landscape

Paxlovid · 1 trial · 1 indication

Phase 3 1
NCT05614349Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community SettingsCOVID-19
ACTIVE NOT_RECRUITING797 Analytics
PHASE3ACTIVE NOT_RECRUITING
Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings
COVID-19
NCT05614349797
Unlock trial analytics
Study Endpoints
Primary Endpoints
All-cause hospitalization or death rate
Day 28
Secondary Endpoints
Time to recovery
Days 0-14
Symptom severity
Days 0-28
Rate of Post-acute sequelae of SARS-CoV-2
90 days and 36 weeks
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
PaxlovidEXPERIMENTALNirmatrelvir/ritonavir (Paxlovid™) BD x 5 days (this arm has been closed of Sept 30th 2024)
Control groupNO_INTERVENTIONUsual care (i.e., supportive care and symptom relief)
Antioxidant Therapy - Intervention (arm 3)EXPERIMENTALAntioxidant therapy (comprising of selenium, zinc, lycopene, and vitamin C)
Interventions
NameTypeDescription
PaxlovidDRUGThis adaptive platform trial will assess therapeutics for SARS-CoV-2 in out-patient settings. The first intervention arm is Paxlovid.
AntioxidantDRUGAntioxidant therapy (comprising of selenium, zinc, lycopene, and vitamin C)
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites6

Inclusion Criteria: * Age 50 years and older or 18-49 with 1 or more chronic high-risk medical conditions, and/or immunosuppression: chronic respiratory disease (including COPD, cystic fibrosis and asthma requiring at least daily use of preventative and/or reliever medication); chronic heart or vas...

Countries:Canada
Unlock Eligibility Criteria
Competitive Landscape -COVID-19 37 trials
CompanyTickerTrialsLead PhaseDrugs
Pfizer Inc.PFE8PHASE3ibuzatrelvir, remdesivir
BioNTech SE Sponsored ADRBNTX3PHASE3BNT162b2
Merck & Co., Inc.MRK1PHASE3Molnupiravir
Invivyd, Inc.IVVD2PHASE3VYD2311-SD, VYD2311-MD
Vanda Pharmaceuticals Inc.VNDA1PHASE3Tradipitant
BioVie Inc. Class ABIVI1PHASE2NE3107
ImmunityBio IncIBRX2PHASE2Anktiva
Traws Pharma, Inc.TRAW1PHASE2Ratutrelvir non-randomised, Paxlovid, Ratutrelvir
GeoVax Labs, Inc.GOVX1PHASE2COVID-19 Vaccine, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1
Unity Health TorontoUBX1PHASE3Paxlovid, Antioxidant
Moderna, Inc.MRNA1 - SPIKEVAX Bivalent BA.1, SPIKEVAX XBB.1.5, SPIKEVAX JN.1
Abbott LaboratoriesABT1N/AUndisclosed
Design Therapeutics, Inc.DSGN1EARLY_PHASE1COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use
Jade Biosciences, Inc.JBIO1N/AUndisclosed
Structure Therapeutics, Inc. Sponsored ADRGPCR1N/AUndisclosed
Co-Diagnostics, Inc.CODX1 - Undisclosed
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT05614349primaryCompletionDate: changed
LOWMay 24, 2026NCT05614349studyFirstPostDate: changed